Baseline characteristics of patients with asthma initiating dupilumab in a real-world setting: the RAPID registry

<bold>Rationale:</bold> Dupilumab, a human monoclonal antibody, blocks interleukins 4/13, key and central drivers of type 2 inflammation. <bold>Aims and Objective:</bold> RAPID (<ext-link>NCT04287621</ext-link>), a global, prospective registry, aimed to characterize patients with asthma initiating dupilumab in real-world clinical practice. Here, we report baseline characteristics of the 704 patients who enrolled in RAPID between March 2020 and July 2023 (119 centers in 9 countries). <bold>Methods:</bold> RAPID enrolled patients (≥12 years) who initiated dupilumab for asthma (primary indication) according to the country-specific prescribing information. Patient demographics, asthma control, lung function, and severity of disease at baseline were collected for analysis. <bold>Results:</bold> Details of baseline characteristics are shown in the <bold>Table</bold>. Most patients were adults, White, female, and on average overweight. 79.7% of the patients had moderate-to-severe asthma based on their use of high and medium-dose ICS at baseline, 23.8% of patients were former smokers and 3.5% were smoking at the time of enrolment. Patients had reduced lung function and poor asthma control as evidenced by mean ACQ-6 score of 2.4. <bold>Conclusions:</bold> Most patients who initiated dupilumab for asthma had a high disease burden, as indicated by low lung function and poor asthma control. Patients were predominantly female, on average overweight, and 27% of patients were current or former smokers. <fig><object-id>erj;64/suppl_68/PA4484/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig>